It will be at least a year before the company starts actual production.
After Bharat Biotech’s permission to manufacture COVID-19 vaccine covaxine, Mumbai-based Hafkin Bio-Pharmaceutical said on Friday that it would take the company at least a year to begin actual production.
A top official said that the state-run company is aiming to produce 22.8 crore vials of vaccine per year.
Talking to reporters in Mumbai, the Managing Director of Hafkaine Bio-Pharmaceutical Corporation Limited, Dr. Sandeep Rathore said, “Our goal is to produce around 22.8 million vaccine vials but it will take us a year to start production.” Hyderabad-based Bharat Biotech and ICMR have developed Kovaxin, one of two vaccines used in the ongoing nationwide COVID-19 vaccination campaign.
“And now we got a contract to produce the vaccine at our Parel facility in Mumbai,” he said.
“In January this year a proposal was put forward due to increasing cases of coronavirus and more vaccines were needed to vaccinate a large number of people. This is an ambitious project that is important from the angle of vaccination for such a large population , “Managing Director of the Maharashtra Government undertaking.
“There will be an internal team and a technical team to set up the raw material production facility. Once we get all the approvals from the center regarding safety and quality standards, we will start production of the vaccine.
Dr. “The installed capacity of the new facility will be 22.8 crore vials per year and we will make maximum use of it,” Rathore said.
.
Leave a Reply